AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...

Natera's Signatera test included in NRG-sponsored bladder cancer study. Credit: Michael Vi / Shutterstock.com. · Medical Device Network · Michael Vi / Shutterstock.com. The above button links to ...

SAN CARLOS, Calif., May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, ...

Add Yahoo as a preferred source to see more of our stories on Google. Molecular residual disease tests analyze blood samples for evidence of cancer cells lingering in the body after treatment with ...

Add Yahoo as a preferred source to see more of our stories on Google. The test has also received a Category 1 recommendation in the NCCN guidelines for Signatera MRD-guided adjuvant atezolizumab.

When Christy Fennewald was 36, she felt a lump in one of her breasts, but a diagnostic ultrasound didn't pick up that it was suspicious. Nine months later, she was diagnosed with breast cancer and ...

Natera, Inc.'s revenue growth remains strong, driven by rapid adoption of Signatera, now covered by Medicare, which should provide recurring revenue and some competitive advantage. Litigation risks ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...